Edition:
United Kingdom

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

16.40USD
22 Jun 2018
Change (% chg)

$0.60 (+3.80%)
Prev Close
$15.80
Open
$15.80
Day's High
$16.40
Day's Low
$15.65
Volume
904,376
Avg. Vol
249,791
52-wk High
$22.70
52-wk Low
$5.30

Select another date:

Mon, Apr 23 2018

BRIEF-Abeona Announces FDA Grants Rmat Designation To ABO-102 Gene Therapy In MPS Iiia

* ABEONA ANNOUNCES FDA GRANTS RMAT DESIGNATION TO ABO-102 GENE THERAPY IN MPS IIIA

BRIEF-Abeona Therapeutics Receives Orphan Drug Designation In The European Union For ABO-202 Gene Therapy Program In Batten Disease

* ABEONA THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ABO-202 GENE THERAPY PROGRAM IN BATTEN DISEASE Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer

* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER

BRIEF-Abeona Therapeutics Appoints Carsten Thiel As Chief Executive Officer

* TIMOTHY J. MILLER WILL REMAIN PRESIDENT AND ASSUME POSITION OF CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics Reports Q4 Loss Per Share $0.19

* ABEONA THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

BRIEF-Abeona Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease

* ABEONA THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN CLN1 DISEASE

BRIEF-Abeona Receives FDA Orphan Drug Status For Gene Therapy To Treat Rare Disease In Newborns

* ABEONA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN INFANTILE BATTEN DISEASE

BRIEF-Abeona Therapeutics Says Gene Therapy ABO-101 Is Well Tolerated

* ABEONA THERAPEUTICS REPORTS ON INITIAL SAFETY AND BIOPOTENCY SIGNALS IN MPS IIIB GENE THERAPY CLINICAL TRIAL

BRIEF-Abeona Receives FDA Regenerative Medicine Advanced Therapy Status For Experimental Gene Therapy For Rare Skin Disorder

* ABEONA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR EB-101 GENE THERAPY IN EPIDERMOLYSIS BULLOSA

Select another date: